Journal
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
Volume 31, Issue 6, Pages 413-416Publisher
KARGER
DOI: 10.1159/000329763
Keywords
Dementia with Lewy bodies; Alzheimer's disease; Dementia; alpha-Synuclein; Serum
Categories
Funding
- University of Tubingen [F1331299]
- German Center for Neurodegenerative Diseases (DZNE)
- Robert Bosch Foundation, Stuttgart, Germany [32.5.1141.0019.0]
Ask authors/readers for more resources
Background/Aims: Detection and differentiation of neuro-degenerative dementias, such as dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), with blood-based biomarkers would facilitate diagnosis and treatment. Methods: By use of a commercially available ELISA kit, we measured alpha-synuclein levels in the serum of 40 DLB patients and controls, and of 80 AD patients. Results: We found significantly reduced alpha-synuclein serum levels in DLB compared to both AD (p = 0.006) and control subjects (p = 0.001), reaching an area under the curve of >0.70. Conclusion: Although these results do not justify a definition of serum alpha-synuclein as a potential single biomarker, results may contribute to a multimarker strategy in DLB diagnosis. Copyright (C) 2011 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available